{"id":49108,"date":"2020-11-26T15:24:58","date_gmt":"2020-11-26T14:24:58","guid":{"rendered":"https:\/\/blogs.bmj.com\/bmj\/?p=49108"},"modified":"2020-12-22T14:41:21","modified_gmt":"2020-12-22T13:41:21","slug":"peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/","title":{"rendered":"Peter Doshi: Pfizer and Moderna\u2019s \u201c95% effective\u201d vaccines\u2014let\u2019s be cautious and first see the full data"},"content":{"rendered":"<p class=\"standfirst\"><span style=\"font-weight: 400\">Only full transparency and rigorous scrutiny of the data will allow for informed decision making, argues Peter Doshi<\/span><\/p>\n<p><!--more--><span style=\"font-weight: 400\">In the United States, all eyes are on Pfizer and Moderna. The topline efficacy results from their experimental covid-19 vaccine trials are astounding at first glance. Pfizer says it recorded 170 covid-19 cases (in 44,000 volunteers), with a remarkable split: 162 in the placebo group versus 8 in the vaccine group. Meanwhile Moderna says 95 of 30,000 volunteers in its ongoing trial got covid-19: 90 on placebo versus 5 receiving the vaccine, leading both companies to claim around 95% efficacy.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Let\u2019s put this in perspective. First, a relative risk reduction is being reported, not absolute risk reduction, which appears to be less than 1%. Second, these results refer to the trials\u2019 primary endpoint of covid-19 of essentially any severity, and importantly <\/span><a href=\"https:\/\/www.bmj.com\/content\/371\/bmj.m4037\"><span style=\"font-weight: 400\">not the vaccine\u2019s ability to save lives<\/span><\/a><span style=\"font-weight: 400\">, nor the <\/span><a href=\"https:\/\/www.npr.org\/sections\/health-shots\/2020\/08\/28\/906797539\/what-a-nasal-spray-vaccine-against-covid-19-might-do-even-better-than-a-shot\"><span style=\"font-weight: 400\">ability to prevent infection<\/span><\/a><span style=\"font-weight: 400\">, nor the efficacy in important subgroups (e.g. frail elderly). Those still remain unknown. Third, these results reflect a time point relatively soon after vaccination, and we know nothing about vaccine performance at 3, 6, or 12 months, so cannot compare these efficacy numbers against other vaccines like influenza vaccines (which are judged over a season). Fourth, children, adolescents, and immunocompromised individuals were <\/span><a href=\"https:\/\/www.bmj.com\/content\/371\/bmj.m4037\"><span style=\"font-weight: 400\">largely excluded<\/span><\/a><span style=\"font-weight: 400\"> from the trials, so we still lack any data on these important populations.<\/span><\/p>\n<p><span style=\"font-weight: 400\">I previously argued that the trials are<\/span><a href=\"https:\/\/www.bmj.com\/content\/371\/bmj.m4037\"> <span style=\"font-weight: 400\">studying the wrong endpoint<\/span><\/a><span style=\"font-weight: 400\">, and for an urgent<\/span><a href=\"https:\/\/www.bmj.com\/content\/371\/bmj.m4058\"> <span style=\"font-weight: 400\">need to correct course<\/span><\/a><span style=\"font-weight: 400\"> and study more important endpoints like prevention of severe disease and transmission in high risk people. Yet, despite the existence of <\/span><a href=\"https:\/\/www.statnews.com\/2020\/11\/09\/expanded-access-not-eua-for-distributing-preapproval-covid-19-vaccines\/\"><span style=\"font-weight: 400\">regulatory mechanisms for ensuring vaccine access while keeping the authorization bar high<\/span><\/a><span style=\"font-weight: 400\"> (which would allow placebo-controlled trials to continue long enough to answer the important question), it\u2019s hard to avoid the impression that sponsors are claiming victory and wrapping up their trials (Pfizer has <\/span><a href=\"https:\/\/www.nature.com\/articles\/d41586-020-03219-y\"><span style=\"font-weight: 400\">already sent trial participants a letter<\/span><\/a><span style=\"font-weight: 400\"> discussing \u201ccrossing over\u201d from placebo to vaccine), and the FDA will now be under enormous pressure to rapidly authorize the vaccines.<\/span><\/p>\n<p><span style=\"font-weight: 400\">But as conversation shifts to vaccine distribution, let\u2019s not lose sight of the evidence. <\/span><a href=\"https:\/\/www.bmj.com\/content\/370\/bmj.m3260\"><span style=\"font-weight: 400\">Independent scrutiny of the underlying trial data<\/span><\/a><span style=\"font-weight: 400\"> will increase trust and credibility of the results. There also might be important limitations to the trial findings we need to be aware of.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Most crucially, we need data-driven assurances that the studies were not inadvertently unblinded, by which I mean investigators or volunteers could make reasonable guesses as to which group they were in. Blinding is most important when measuring subjective endpoints like symptomatic covid-19, and differences in post-injection side-effects between vaccine and placebo might have allowed for educated guessing. Past placebo-controlled <\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10493337\/\"><span style=\"font-weight: 400\">trials<\/span><\/a> <a href=\"https:\/\/doi.org\/10.1007\/bf02595754\"><span style=\"font-weight: 400\">of<\/span><\/a> <a href=\"https:\/\/doi.org\/10.1001\/jama.284.13.1655\"><span style=\"font-weight: 400\">influenza<\/span><\/a><span style=\"font-weight: 400\"> vaccine were not able to fully maintain blinding of vaccine status, and the recent \u201chalf dose\u201d mishap in the Oxford covid-19 vaccine trial was <\/span><a href=\"https:\/\/www.reuters.com\/article\/us-health-coronavirus-astrazeneca-dosing\/dosing-error-turns-into-lucky-punch-for-astrazeneca-and-oxford-idUSKBN28327Q\"><span style=\"font-weight: 400\">apparently only noticed<\/span><\/a><span style=\"font-weight: 400\"> because of milder-than-expected side-effects. (And that is just one of <\/span><a href=\"https:\/\/www.wired.com\/story\/the-astrazeneca-covid-vaccine-data-isnt-up-to-snuff\/\"><span style=\"font-weight: 400\">many<\/span><\/a> <a href=\"https:\/\/www.nytimes.com\/2020\/11\/25\/business\/coronavirus-vaccine-astrazeneca-oxford.html\"><span style=\"font-weight: 400\">concerns<\/span><\/a><span style=\"font-weight: 400\"> with the Oxford trial.)<\/span><\/p>\n<p><span style=\"font-weight: 400\">In contrast to a normal saline placebo, <\/span><a href=\"https:\/\/doi.org\/10.1101\/2020.08.17.20176651\"><span style=\"font-weight: 400\">early<\/span><\/a> <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2028436\"><span style=\"font-weight: 400\">phase<\/span><\/a> <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2022483\"><span style=\"font-weight: 400\">trials<\/span><\/a><span style=\"font-weight: 400\"> suggested that systemic and local adverse events are common in those receiving vaccine. In one Pfizer <\/span><a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2027906\"><span style=\"font-weight: 400\">trial<\/span><\/a><span style=\"font-weight: 400\">, for example, more than half of the vaccinated participants experienced headache, muscle pain and chills\u2014but the early phase trials were small, with large margins of error around the data. Few details from the large phase 3 studies have been released thus far. <\/span><a href=\"https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy\"><span style=\"font-weight: 400\">Moderna\u2019s press release<\/span><\/a><span style=\"font-weight: 400\"> states that 9% experienced grade 3 myalgia and 10% grade 3 fatigue; <\/span><a href=\"https:\/\/investors.pfizer.com\/investor-news\/press-release-details\/2020\/Pfizer-and-BioNTech-Conclude-Phase-3-Study-of-COVID-19-Vaccine-Candidate-Meeting-All-Primary-Efficacy-Endpoints\/default.aspx\"><span style=\"font-weight: 400\">Pfizer\u2019s statement<\/span><\/a><span style=\"font-weight: 400\"> reported 3.8% experienced grade 3 fatigue and 2% grade 3 headache. Grade 3 adverse events are considered severe, defined as preventing daily activity. Mild and moderate severity reactions are bound to be far more common.<\/span><\/p>\n<p><span style=\"font-weight: 400\">One way the trial\u2019s raw data could facilitate an informed judgment as to whether any potential unblinding might have affected the results is by analyzing how often people with symptoms of covid-19 were referred for confirmatory SARS-CoV-2 testing. Without a referral for testing, a suspected covid-19 case could not become a confirmed covid-19 case, and thus is a crucial step in order to be counted as a primary event: lab-confirmed, symptomatic covid-19. Because some of the adverse reactions to the vaccine are themselves also symptoms of covid-19 (e.g. fever, muscle pain), one might expect a far larger proportion of people receiving vaccine to have been swabbed and tested for SARS-CoV-2 than those receiving placebo.<\/span><\/p>\n<p><span style=\"font-weight: 400\">This assumes all people with symptoms would be tested, as one might expect would be the case. However the trial protocols for Moderna and <\/span><a href=\"https:\/\/pfe-pfizercom-d8-prod.s3.amazonaws.com\/2020-09\/C4591001_Clinical_Protocol.pdf\"><span style=\"font-weight: 400\">Pfizer\u2019s studies<\/span><\/a><span style=\"font-weight: 400\"> contain explicit language instructing investigators to use their clinical judgment to decide whether to refer people for testing. <\/span><a href=\"https:\/\/www.modernatx.com\/sites\/default\/files\/mRNA-1273-P301-Protocol.pdf\"><span style=\"font-weight: 400\">Moderna puts it this way<\/span><\/a><span style=\"font-weight: 400\">:<\/span><\/p>\n<p><span style=\"font-weight: 400\">\u201c<em>It is important to note that some of the symptoms of COVID-19 overlap with solicited systemic ARs that are expected after vaccination with mRNA-1273 (eg, myalgia, headache, fever, and chills). During the first 7 days after vaccination, when these solicited ARs are common, Investigators should use their clinical judgement to decide if an NP swab should be collected.<\/em>\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400\">This amounts to asking investigators to make guesses as to which intervention group patients were in. But when the disease and the vaccine side-effects overlap, how is a clinician to judge the cause without a test? And why were they asked, anyway?<\/span><\/p>\n<p><span style=\"font-weight: 400\">Importantly, the instructions only refer to the first seven days following vaccination, leaving unclear what role clinician judgment could play in the key days afterward, when cases of covid-19 could begin counting towards the primary endpoint. (For Pfizer, 7 days after the 2nd dose. For Moderna, 14 days.)<\/span><\/p>\n<p><span style=\"font-weight: 400\">In a proper trial, all cases of covid-19 should have been recorded, no matter which arm of the trial the case occurred in. (In epidemiology terms, there should be no ascertainment bias, or differential measurement error). It\u2019s even become common sense in the Covid era: \u201ctest, test, test.\u201d But if referrals for testing were not provided to all individuals with symptoms of covid-19\u2014for example because an assumption was made that the symptoms were due to side-effects of the vaccine\u2014cases could go uncounted.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Data on pain and fever reducing medicines also deserve scrutiny. Symptoms resulting from a SARS-CoV-2 infection (e.g. fever or body aches) can be suppressed by pain and fever reducing medicines. If people in the vaccine arm took such medicines prophylactically, more often, or for a longer duration of time than those in the placebo arm, this could have led to greater suppression of covid-19 symptoms following SARS-CoV-2 infection in the vaccine arm, translating into a reduced likelihood of being suspected for covid-19, reduced likelihood of testing, and therefore reduced likelihood of meeting the primary endpoint. But in such a scenario, the effect was driven by the medicines, not the vaccine.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Neither Moderna nor Pfizer have released any samples of written materials provided to patients, so it is unclear what, if any, instructions patients were given regarding the use of medicines to treat side effects following vaccination, but the informed consent form for <\/span><a href=\"https:\/\/www.henryford.com\/-\/media\/files\/henry-ford\/hcp\/covid19\/j-and-j-covid19-study\/informed-consent-form--irb-jj-trial.pdf\"><span style=\"font-weight: 400\">Johnson and Johnson\u2019s vaccine trial<\/span><\/a><span style=\"font-weight: 400\"> provides such a recommendation:<\/span><\/p>\n<p><span style=\"font-weight: 400\">\u201cFollowing administration of Ad26.COV2.S, fever, muscle aches and headache appear to be more common in younger adults and can be severe. For this reason, we recommend you take a fever reducer or pain reliever if symptoms appear after receiving the vaccination, or upon your study doctor\u2019s recommendation.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400\">There may be much more complexity to the \u201c95% effective\u201d announcement than meets the eye\u2014or perhaps not. Only full transparency and rigorous scrutiny of the data will allow for informed decision making. The data must be made public.<\/span><\/p>\n<p><a href=\"https:\/\/www.bmj.com\/sites\/default\/files\/doshi_95_percent_spanish_translation_je_jal_je_jal_1q_pd_final_-_google_docs.pdf\">Spanish translation<\/a> of this article<\/p>\n<p><a href=\"https:\/\/www.bmj.com\/sites\/default\/files\/pd_opinion_bmj_deutsch_die_korr13.12_ukas_clean_docx_-_google_docs.pdf\">German translation<\/a> of this article<\/p>\n<p><em><span style=\"font-weight: 400\"><strong>Peter Doshi<\/strong>, associate editor, <\/span><\/em><span style=\"font-weight: 400\">The BMJ.<\/span><\/p>\n<p><em><b>Competing interests: <\/b><span style=\"font-weight: 400\">I have been pursuing the public release of vaccine trial protocols, and have co-signed open letters calling for independence and transparency in covid-19 vaccine related decision making.<\/span><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Only full transparency and rigorous scrutiny of the data will allow for informed decision making, argues Peter Doshi [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/\">More&#8230;<\/a><\/p>\n","protected":false},"author":66,"featured_media":49009,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[116],"tags":[],"class_list":["post-49108","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-editors-at-large"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Peter Doshi: Pfizer and Moderna\u2019s \u201c95% effective\u201d vaccines\u2014let\u2019s be cautious and first see the full data - The BMJ<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Peter Doshi: Pfizer and Moderna\u2019s \u201c95% effective\u201d vaccines\u2014let\u2019s be cautious and first see the full data - The BMJ\" \/>\n<meta property=\"og:description\" content=\"Only full transparency and rigorous scrutiny of the data will allow for informed decision making, argues Peter Doshi [...]More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/\" \/>\n<meta property=\"og:site_name\" content=\"The BMJ\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/bmjdotcom\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-26T14:24:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-12-22T13:41:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/bmj\/files\/2020\/11\/coronavirus_vaccine_3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"540\" \/>\n\t<meta property=\"og:image:height\" content=\"350\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"julietwalker\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:site\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"julietwalker\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/11\\\/26\\\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/11\\\/26\\\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\\\/\"},\"author\":{\"name\":\"julietwalker\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/373707d32533c2cbca204980b8cd3493\"},\"headline\":\"Peter Doshi: Pfizer and Moderna\u2019s \u201c95% effective\u201d vaccines\u2014let\u2019s be cautious and first see the full data\",\"datePublished\":\"2020-11-26T14:24:58+00:00\",\"dateModified\":\"2020-12-22T13:41:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/11\\\/26\\\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\\\/\"},\"wordCount\":1306,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/11\\\/26\\\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2020\\\/11\\\/coronavirus_vaccine_3.jpg\",\"articleSection\":[\"Editors at large\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/11\\\/26\\\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/11\\\/26\\\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/11\\\/26\\\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\\\/\",\"name\":\"Peter Doshi: Pfizer and Moderna\u2019s \u201c95% effective\u201d vaccines\u2014let\u2019s be cautious and first see the full data - The BMJ\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/11\\\/26\\\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/11\\\/26\\\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2020\\\/11\\\/coronavirus_vaccine_3.jpg\",\"datePublished\":\"2020-11-26T14:24:58+00:00\",\"dateModified\":\"2020-12-22T13:41:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/11\\\/26\\\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/11\\\/26\\\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/11\\\/26\\\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2020\\\/11\\\/coronavirus_vaccine_3.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2020\\\/11\\\/coronavirus_vaccine_3.jpg\",\"width\":540,\"height\":350,\"caption\":\"A vaccine is a biological preparation that provide\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/11\\\/26\\\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Peter Doshi: Pfizer and Moderna\u2019s \u201c95% effective\u201d vaccines\u2014let\u2019s be cautious and first see the full data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"name\":\"The BMJ\",\"description\":\"Helping doctors make better decisions.\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\",\"name\":\"The BMJ\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"width\":852,\"height\":568,\"caption\":\"The BMJ\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/bmjdotcom\\\/\",\"https:\\\/\\\/x.com\\\/bmj_latest\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/373707d32533c2cbca204980b8cd3493\",\"name\":\"julietwalker\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/34f10b717c81464cc7a2879c84cd30078f63b5a901e12905a02abd9d1ea9ec90?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/34f10b717c81464cc7a2879c84cd30078f63b5a901e12905a02abd9d1ea9ec90?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/34f10b717c81464cc7a2879c84cd30078f63b5a901e12905a02abd9d1ea9ec90?s=96&d=mm&r=g\",\"caption\":\"julietwalker\"},\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/author\\\/julietwalker\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Peter Doshi: Pfizer and Moderna\u2019s \u201c95% effective\u201d vaccines\u2014let\u2019s be cautious and first see the full data - The BMJ","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/","og_locale":"en_US","og_type":"article","og_title":"Peter Doshi: Pfizer and Moderna\u2019s \u201c95% effective\u201d vaccines\u2014let\u2019s be cautious and first see the full data - The BMJ","og_description":"Only full transparency and rigorous scrutiny of the data will allow for informed decision making, argues Peter Doshi [...]More...","og_url":"https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/","og_site_name":"The BMJ","article_publisher":"https:\/\/www.facebook.com\/bmjdotcom\/","article_published_time":"2020-11-26T14:24:58+00:00","article_modified_time":"2020-12-22T13:41:21+00:00","og_image":[{"width":540,"height":350,"url":"https:\/\/blogs.bmj.com\/bmj\/files\/2020\/11\/coronavirus_vaccine_3.jpg","type":"image\/jpeg"}],"author":"julietwalker","twitter_card":"summary_large_image","twitter_creator":"@bmj_latest","twitter_site":"@bmj_latest","twitter_misc":{"Written by":"julietwalker","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/"},"author":{"name":"julietwalker","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/373707d32533c2cbca204980b8cd3493"},"headline":"Peter Doshi: Pfizer and Moderna\u2019s \u201c95% effective\u201d vaccines\u2014let\u2019s be cautious and first see the full data","datePublished":"2020-11-26T14:24:58+00:00","dateModified":"2020-12-22T13:41:21+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/"},"wordCount":1306,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2020\/11\/coronavirus_vaccine_3.jpg","articleSection":["Editors at large"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/","url":"https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/","name":"Peter Doshi: Pfizer and Moderna\u2019s \u201c95% effective\u201d vaccines\u2014let\u2019s be cautious and first see the full data - The BMJ","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2020\/11\/coronavirus_vaccine_3.jpg","datePublished":"2020-11-26T14:24:58+00:00","dateModified":"2020-12-22T13:41:21+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/#primaryimage","url":"https:\/\/blogs.bmj.com\/bmj\/files\/2020\/11\/coronavirus_vaccine_3.jpg","contentUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2020\/11\/coronavirus_vaccine_3.jpg","width":540,"height":350,"caption":"A vaccine is a biological preparation that provide"},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/11\/26\/peter-doshi-pfizer-and-modernas-95-effective-vaccines-lets-be-cautious-and-first-see-the-full-data\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/bmj\/"},{"@type":"ListItem","position":2,"name":"Peter Doshi: Pfizer and Moderna\u2019s \u201c95% effective\u201d vaccines\u2014let\u2019s be cautious and first see the full data"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/bmj\/#website","url":"https:\/\/blogs.bmj.com\/bmj\/","name":"The BMJ","description":"Helping doctors make better decisions.","publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/bmj\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/bmj\/#organization","name":"The BMJ","url":"https:\/\/blogs.bmj.com\/bmj\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","contentUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","width":852,"height":568,"caption":"The BMJ"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/bmjdotcom\/","https:\/\/x.com\/bmj_latest"]},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/373707d32533c2cbca204980b8cd3493","name":"julietwalker","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/34f10b717c81464cc7a2879c84cd30078f63b5a901e12905a02abd9d1ea9ec90?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/34f10b717c81464cc7a2879c84cd30078f63b5a901e12905a02abd9d1ea9ec90?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/34f10b717c81464cc7a2879c84cd30078f63b5a901e12905a02abd9d1ea9ec90?s=96&d=mm&r=g","caption":"julietwalker"},"url":"https:\/\/blogs.bmj.com\/bmj\/author\/julietwalker\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/49108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/users\/66"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/comments?post=49108"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/49108\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/media\/49009"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/media?parent=49108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/categories?post=49108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/tags?post=49108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}